The Application of Continuous Blood Glucose Monitoring in Optimizing the Management of Type 2 Diabetes

Launched by PEKING UNIVERSITY · Jul 30, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how continuous glucose monitoring (CGM) can help people with type 2 diabetes better manage their blood sugar levels. Unlike traditional finger-prick tests, CGM devices track blood sugar continuously throughout the day, giving real-time information that can help patients and doctors make more informed decisions. The study is taking place in community health centers in China and aims to see if using CGM improves blood sugar control, patient satisfaction, and overall quality of life compared to regular monitoring methods.

Adults with type 2 diabetes who have been diagnosed for at least one year and live in the Yinzhou District of Ningbo may be eligible to join. Pregnant women, people with other specific types of diabetes, or those with certain serious health issues are not eligible. Participants will be randomly assigned to either use the CGM device during several two-week periods over six months or continue their usual blood sugar monitoring. Those using CGM will get training on how to use the device. Throughout the study, researchers will also talk to healthcare providers and patients to understand what helps or makes it harder to use CGM in everyday healthcare. This information will help improve diabetes care for many people in the community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ① Age ≥ 18 years old; ② There is a previous diagnosis of T2DM in the electronic medical record system of Qianhu Hospital and Fuming Street Community Health Service Center, and the diagnosis has been made for 1 year or more; ③ Resident with permanent registered residence registration who has filed in the health records of residents in Yinzhou District.
• Exclusion Criteria:
• • ① Pregnant women; ② Type 1 diabetes, adult latent autoimmune diabetes, special type diabetes (such as post pancreatic surgery, monogenic diabetes); ③ Patients who are currently using or have previously used hormone drugs that may affect blood sugar levels; ④ Patients with severe renal insufficiency (eGFR\<30ml/m \^ 2, or undergoing hemodialysis); ⑤ Patients with severe liver dysfunction (ALT or AST greater than 3 times the upper limit of normal); ⑥ Tumor patients.